The interleukin-1 pathway as a treatment target in early-stage hidradenitis suppurativa?
- PMID: 37427780
- DOI: 10.1093/bjd/ljad225
The interleukin-1 pathway as a treatment target in early-stage hidradenitis suppurativa?
Conflict of interest statement
Conflicts of interest: I.S. declares no conflicts of interest. S.G. has been an advisor and/or has received speakers’ honoraria and/or received grants from and/or participated in clinical trials for the following companies: AbbVie, Affibody, Akari Therapeutics, Almirall Hermal, Amgen, Argenx, Aristea Therapeutics, Bristol-Myers Squibb, Boehringer-Ingelheim, Celgene, Dermira, Eli Lilly, Galderma, Hexal, Incyte, Janssen-Cilag, Klinge Pharma, Kymab, Leo Pharma, Medac, MSD, Neubourg Skin Care, Novartis, Pfizer, Pierre Fabre, Principia Biopharma, Regeneron Pharmaceutical, Sandoz Biopharmaceuticals, Sanofi-Aventis, Trevi Therapeutics and UCB Pharma.
Comment on
-
Targeting the NLRP3 inflammasome reduces inflammation in hidradenitis suppurativa skin.Br J Dermatol. 2023 Sep 15;189(4):447-458. doi: 10.1093/bjd/ljad184. Br J Dermatol. 2023. PMID: 37243544
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical